In a report released yesterday, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on 9 Meters Biopharma (NMTR – Research Report), with a price target of $4.00. The company's shares closed last Tuesday at $0.29, close to its 52-week low of $0.22. According to TipRanks.com, Raja is a 1-star analyst with an average return of -1.1% and a 32.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Oncternal Therapeutics, and Caladrius Biosciences. 9 Meters Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $3.67.
https://www.tipranks.com/news/blurbs/brookline-capital-markets-thinks-9-meters-biopharmas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more 9 Meters Biopharma Charts.